Especially, two oral kinase inhibitors, idelalisib (PI3K inhibitor) and ibrutinib (BTK inhibitor), have changed the standard of care for CLL patients in both the relapsed and frontline settings [13]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.